VIVUS News

Dissident Vivus Inc. shareholder First Manhattan Co. nominated three more director candidates following the drug maker's expansion of its board size.

In preparation for sales of the new anti-obesity drug Belviq on June 7th, Arena scheduled six events in six weeks including two post-launch. The launch will usher in a $65 million milestone payment from Eisai , more than many movies make and 16-times more than Vivus' first quarter's revenue.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! MOUNTAIN VIEW, Calif., May 22, 2013 -- VIVUS, Inc.

In this article I will discuss why I believe public awareness of Arena Pharmaceuticals' Belviq, and to a lesser extent Vivus' Qsymia , will occur at a much quicker rate and on a much larger scale than that which occurred with the now infamous and wildly successful FenPhen drug of the 1990s.

The Food and Drug Administration approved the weight-loss therapy Belviq from Arena Pharmaceuticals, Inc.

On The Fly: Analyst Downgrade Summary Today's noteworthy downgrades include: AVG Technologies downgraded to Neutral from Buy at Goldman... Cigna downgraded to Hold from Buy at Jefferies... Cree downgraded to Neutral from Buy at Sterne Agee... Melco Crown downgraded to Neutral from Buy at UBS... SolarCity downgraded to Neutral from Buy at Roth ... (more)

A sharp drop in Arena Pharmaceuticals followed after the company reported quarterly earnings and a withdrawal of its Marketing Authorization Application in the EU.

Vivus Inc. appointed two additional directors, increasing the size of its board by 50 percent in less than a month amid pressure from shareholders over the company's strategy for promoting its obesity drug Qsymia.

Biotech company VIVUS, Inc. has struggled to pick up sales of its obesity medication Qsymia since the drug was launched in September.

APB Financial Group today announced that Damien Park, Managing Partner at Hedge Fund Solutions, will interview two of First Manhattan's nominees for election to VIVUS Inc.'s Board of Directors as part of APB's ongoing series of interviews on shareholder activism.

Vivus has had a challenging year. The company launched its highly touted anti-obesity drug, Qsymia, last September only to see sales numbers dribble in instead of the blockbuster sales some were anticipating when the FDA approval was announced earlier in the summer.

Michael G. King, the No. 1 pharmaceuticals analyst for 2012, won by making bets on drug makers that other analysts had ignored.

Good day, ladies and gentlemen, and welcome to the VIVUS First Quarter 2013 Conference Call.

Vivus Inc., maker of the obesity drug Qsymia, is in talks with large pharmaceutical companies to explore ways to increase sales of the medicine, which have disappointed investors.

VIVUS released its earnings data on Wednesday. The company reported EPS for the quarter, missing the Thomson Reuters consensus estimate of by $0.02, Analyst Ratings.Net reports.

ROB Insight is The Globe and Mail's exclusive feature led by a team of award-winning editors and writers who provide you with in-depth analysis on breaking business news and the issues that matter most.

VIVUS, Inc. Announces Richard Fante , Former President U.S. and CEO North America, AstraZeneca PLC , to Serve as Senior Advisor Staying up-to-date has never been simpler.

Responding to news that the company would withdraw its MAA for Belviq from the EMA, shares of Arena Pharmaceuticals tanked by 9.2% last Friday as investors questioned whether obesity drugs had a future in the EU market.

The firm currently has an "overweight" rating on the stock. A number of other firms have also recently commented on VVUS.

The broad markets are staying close to the flatline today, after hitting fresh all-time peaks last week.